

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

Attorney Docket No. 13587.338

First Inventor RAYMOND, Vincent

Title Optineurin Nucleic Acid Molecules and Uses Thereof

Express Mail Label No.

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☐ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 125]
(preferred arrangement set forth below)
- Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the invention
 - Brief Summary of the invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 14]
5. Oath or Declaration [Total Pages 6*]
- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63 (d))
(for a continuation/divisional with Box 18 completed)
- i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO:Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☒ Computer Readable Form (CRF)
- b. Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
- ii. ☒ paper
- c. ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATIONS PARTS

9. ☒ Assignment Papers (cover sheet & document(s))
10. ☐ 37 C.F.R. §3.73(b) Statement ☒ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other:

18. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: ___ / ___
Prior application information: Examiner: ___ Group / Art Unit: ___


For **CONTINUATION** or **DIVISIONAL APPS** only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS☒ Customer Number or Bar Code Label

(Insert Customer Number or Bar Code label here)

or ☐ Correspondence address below

Name	David R. Marsh					28381
PATENT, TRADEMARK OFFICE						
Address	Arnold & Porter					
555 Twelfth Street, N.W.						
City	Washington	State	DC	Zip Code	20004	
Country	US	Telephone	(202) 942-5000	Fax	(202) 942-5999	

Name (Print/Type)	David R. Marsh	Registration No. (Attorney/Agent)	41,404
Signature		Date	March 6, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

* With attached papers.

ARNOLD & PORTER

David R. Marsh, Ph.D.
David_Marsh@aporter.com

202.942.5068
202.942.5999 Fax

555 Twelfth Street, NW
Washington, DC 20004-1206

March 6, 2002

Box Patent Application

Commissioner for Patents
Washington, DC 20231

Re: U.S. Non-Provisional Utility Application
Filed: March 6, 2002
For: Optineurin Nucleic Acid Molecules and Uses Thereof
Inventors: Vincent RAYMOND *et al.*
Atty Docket: 13587.338

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (PTO):

1. Utility Patent Application Transmittal (PTO/SB/05);
2. U.S. Non-Provisional Utility Application entitled:

Optineurin Nucleic Acid Molecules and Uses Thereof

and naming as inventors:

Vincent RAYMOND, Jean MORISSETTE, and Erwin SI;

the application consisting of:

- a. a specification containing:
 - (i). 114 pages of a description prior to the claims;
 - (ii). 10 pages of claims (51 claims);
 - (iii). 14 pages of drawings (Figures 1, 2, and 3);
 - (iv). a one (1) page abstract;
 - (v). a paper copy of the sequence listing (133 pages);
3. a sequence listing in Computer Readable Form (CRF), on floppy diskette;
4. a Statement Regarding Sequence Submission;
5. a Combined Declaration and Power of Attorney for Patent Application executed by inventors Vincent Raymond and Jean Morissette (3 pages, with attached application containing 272 total pages);
6. a Combined Declaration and Power of Attorney for Patent Application executed by inventor Erwin Si (3 pages, with attached application containing 272 total pages);

ARNOLD & PORTER

Commissioner for Patents
Atty. Dkt.: 13587.338
March 6, 2002
Page 2

7. Form PTO-1595 (Recordation Form Cover Sheet);
8. an Assignment executed by inventors Vincent Raymond and Jean Morissette (2 pages);
9. an Assignment executed by inventor Erwin Se (2 pages);
10. an Information Disclosure Statement;
11. Form PTO-1449 (1 page), with 10 accompanying documents;
12. check No. 153132 in the amount of \$2,222.00 to cover the basic filing fee and extra claims fee;
13. check No. 153133 in the amount of \$40.00 to cover the recordation fee for the assignment; and
14. two (2) return postcards.

Submitted herewith is a sequence listing in Computer Readable Form (CFR), on floppy diskette. The sequence listing in Computer Readable Form (CRF) contains one file called "13587_338.txt" which is 157,210 bytes in size (measured in MS-DOS) and was created on March 1, 2002.

Please stamp one of the two attached postcards with the filing date of these documents and return it to our courier, and stamp the other prepaid postcard with the filing date and unofficial application number and return it as soon as possible.

Applicant does not believe that any fees other than the application filing fee (\$2,222) are due in conjunction with this filing. However, should any additional fees be required, the Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1824 referencing docket number 13587.338. A duplicate copy of this letter is enclosed.

Very truly yours,



David R. Marsh (Reg. No. 41,408)

Enclosures

20020306 13587.338

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Vincent RAYMOND *et al.*

Art Unit: To Be Assigned

Appln. No.: To Be Assigned

Examiner: To Be Assigned

Filed: March 6, 2002

Atty. Docket: 13587.338

For: Optineurin Nucleic Acid
Molecules and Uses Thereof


Statement Regarding Sequence Submission

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer-readable copy of the Sequence Listing submitted herewith in the above-mentioned application are the same.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)

Date: March 6, 2002

ARNOLD & PORTER
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile

200901031030502